Development and characterization of monoclonal antibodies specific for mouse and human Fc? receptors
Development and characterization of monoclonal antibodies specific for mouse and human Fc? receptors
Fc?Rs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore, they are key determinants of mAb immunotherapy, with mAb isotype and Fc?R interaction governing therapeutic efficacy. Critical to understanding the biology of this complex family of receptors are reagents that are robust and highly specific for each receptor. In this study, we describe the development and characterization of mAb panels specific for both mouse and human Fc?R for use in flow cytometry, immunofluorescence, and immunocytochemistry. We highlight key differences in expression between the two species and also patterns of expression that will likely impact on immunotherapeutic efficacy and translation of therapeutic agents from mouse to clinic.
5503-5516
Tutt, A.
46ce577b-aea1-412d-84ea-fc4dab794469
James, S.
764c80e3-5bea-4b34-a871-b43f87ef97b0
Laversin, S.A.
e9122da5-bfb0-4260-b7db-659fb855e898
Tipton, T.R.W.
a0a94b14-7d09-4411-b988-84c9d39eb0d6
Ashton-Key, M.
5111ac18-7d4f-4ef0-9c71-0a44c37aaed4
French, R.R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Hussain, K.
9468f252-81d0-4251-b800-702433b610f8
Vaughan, A. T.
bfb2ceab-a592-457e-89f9-00fcd1dddbdb
Dou, L.
78292b26-0ece-40d8-85fd-d24661c3ca15
Earley, A.
aa795fdf-fd74-474c-91ad-5c2bd597213a
Dahal, L.N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Lu, C.
456c6d86-4b34-4ba7-917c-83ebf1f4c08b
Dunscombe, M.
4b6f0274-89a2-423b-8094-0cc64ffe3722
Chan, H.T.C.
b109c93f-7e9a-44ee-ad12-da757b1b11fc
Penfold, C.A.
400d743e-a639-45ea-a027-5b778800f6d3
Kim, J.H.
449c77b0-dc96-425b-8fad-4b5e214fa93f
Potter, E.A.
7828a574-b547-4955-961f-a4a17ed9d491
Mockridge, C.I.
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Oldham, R.J.
f43d1416-0b93-4dfd-a504-2850cb43e87e
Cox, K.L.
7305c27e-9cdc-4e37-b994-ac55d7d1dfd2
Lim, S.H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Teige, I.
2f8d7623-431d-4c93-85a4-b36e367a518f
Frendeus, B.
ea6161a4-2041-4317-9802-95f623219fa6
Glennie, M.J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Beers, S.A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
1 December 2015
Tutt, A.
46ce577b-aea1-412d-84ea-fc4dab794469
James, S.
764c80e3-5bea-4b34-a871-b43f87ef97b0
Laversin, S.A.
e9122da5-bfb0-4260-b7db-659fb855e898
Tipton, T.R.W.
a0a94b14-7d09-4411-b988-84c9d39eb0d6
Ashton-Key, M.
5111ac18-7d4f-4ef0-9c71-0a44c37aaed4
French, R.R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Hussain, K.
9468f252-81d0-4251-b800-702433b610f8
Vaughan, A. T.
bfb2ceab-a592-457e-89f9-00fcd1dddbdb
Dou, L.
78292b26-0ece-40d8-85fd-d24661c3ca15
Earley, A.
aa795fdf-fd74-474c-91ad-5c2bd597213a
Dahal, L.N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Lu, C.
456c6d86-4b34-4ba7-917c-83ebf1f4c08b
Dunscombe, M.
4b6f0274-89a2-423b-8094-0cc64ffe3722
Chan, H.T.C.
b109c93f-7e9a-44ee-ad12-da757b1b11fc
Penfold, C.A.
400d743e-a639-45ea-a027-5b778800f6d3
Kim, J.H.
449c77b0-dc96-425b-8fad-4b5e214fa93f
Potter, E.A.
7828a574-b547-4955-961f-a4a17ed9d491
Mockridge, C.I.
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Oldham, R.J.
f43d1416-0b93-4dfd-a504-2850cb43e87e
Cox, K.L.
7305c27e-9cdc-4e37-b994-ac55d7d1dfd2
Lim, S.H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Teige, I.
2f8d7623-431d-4c93-85a4-b36e367a518f
Frendeus, B.
ea6161a4-2041-4317-9802-95f623219fa6
Glennie, M.J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Beers, S.A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.S.
ec97f80e-f3c8-49b7-a960-20dff648b78c